Company ProfilePremium

Bod Australia Limited

Company Profile Analysis

Ticker: BDA.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Bod Australia Limited - Company showcase

Year Founded & Workforce

2014

7 Employees

Bod Australia Limited logo

Bod Australia Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Bod Australia Limited Overview

Bod Science is a micro-cap Australian medicinal cannabis distributor that began life as a natural-health and skincare start-up and, between 2017 and 2023, repositioned itself as a "cannabis-centric" drug-development company. Its core franchise was MediCabilis, a GMP-certified, CBD-dominant medicinal cannabis oil supplied to prescribing doctors in Australia and the UK, complemented by consumer CBD/hemp wellness products (including the UK CBII brand and an exclusive supply relationship with Hong Kong-listed Health & Happiness Group) and an over-the-counter herbal range. Revenue peaked at A$6.6m in FY2021 before collapsing as the Australian market migrated to THC flower and the H&H exclusivity lapsed. An expensive Schedule 3 insomnia trial missed its primary endpoint in 2023, a capital raise failed in November 2023, and the company entered administration. Today it is a four-employee THC-flower distribution business (Bod Flora, FGW, MediCabilis) being absorbed into private grower Biortica Agrimed via a court-sanctioned DOCA share transfer.


Company's own description (latest annual report, FY2025)

The FY2025 Deed Administrator's Report defines the principal activity narrowly as the distribution of therapeutic medicinal cannabis products, based on GMP-certified cannabis extracts, for medical markets in Australia and the United Kingdom. This compares with the broader FY2023 description, which covered both (i) development and distribution of therapeutic medicinal cannabis products for medical markets in Australia and the UK and (ii) development of premium CBD and hemp products for consumer markets in Australia, the UK, Europe and the United States.

Independent characterisation

Bod has never manufactured at scale; it is an asset-light brand owner and distributor that outsources extraction, formulation and finished-goods manufacture to contract manufacturers and buys inventory (by FY2025, exclusively from Australian suppliers in AUD, per the FY2025 risk section). Its economic model has passed through three phases:

  1. 2014–2017: natural-health/OTC herbal brand owner. Imported European clinically-studied herbal extracts (e.g., Flexofytol turmeric extract for joint health; Sedistress passion-flower extract for stress/sleep) and distributed via pharmacy wholesalers.

  2. 2018–2023: cannabis-centric healthcare company. MediCabilis (CBD-dominant oil) sold under Australia's Special Access Scheme (SAS-B) and Authorised Prescriber pathways and in the UK via specials; CBD wellness products in the UK, EU (Netherlands) and US; white-label/exclusive CBD supply to Health & Happiness (H&H) Group; R&D tax-incentive-funded clinical programs (Phase I, Schedule 3 insomnia Phase IIb, long-COVID study) and a delivery-technology acquisition (Aqua Phase).

  3. Dec 2023–present: THC-flower distributor under administration. First THC product launched in Australia in December 2023; 12 THC SKUs by FY2025; THC accounted for 73% of FY2025 medical sales; R&D, marketing and international operations essentially shut down; operating costs funded by Biortica.

Revenue model mix

Revenue type (AUD Mn)FY2022FY2023FY2024FY2025
Product sales – sale of goods (AUD M)3.4251.6680.8651.485
Royalty / licensing (AUD M)0.1760.0500.0100
Revenue from contracts with customers (AUD M)3.6011.7180.8761.485
R&D tax incentive (AUD M)1.3381.3571.9810.678
Biortica funding income (AUD M)000.9671.171

Source: FY2023 Appendix 4E (Notes 4–6); FY2025 Appendix 4E (Notes 4–6). FY2023 reported R&D incentive within "revenue"; FY2024–FY2025 reclassified it to "other income". The company has no subscription or service revenue. Royalty income derived from the OTC CBD/Hemp segment (H&H-related arrangements).

Value-chain position, customers and end-markets

Value chain: Brand/IP owner and regulatory sponsor → contract GMP manufacturers (outsourced) → pharmaceutical wholesalers/distributors (Symbion, API historically; five distributors by FY2025) → pharmacies and prescribing clinics → patients.

Customer concentration: Three major customers accounted for 64% of FY2023 revenue (A$1.07m) and 67% of FY2025 sales revenue (A$1.00m); two major customers accounted for 61% of FY2024 sales (FY2023 and FY2025 Appendix 4E, Note 4).

End-markets (historic): Australian prescribed medicinal cannabis; UK prescribed medicinal cannabis (specials); UK/EU/US consumer CBD wellness; Australian OTC herbal supplements; China/Asia via H&H (indirect).

End-markets (current): Australian prescribed medicinal cannabis (THC flower and CBD oils); negligible UK residual sales (A$8,188 in FY2025).

Strategy

Stated strategy themes

FY2023 (pre-administration): Advance the medical cannabis division and R&D; commercialise the Schedule 3 CBD insomnia product through SAS-B and, on ARTG registration, through Australian pharmacies via an exclusive Arrotex Pharmaceuticals distribution agreement; commercialise Aqua Phase as a drug-delivery platform and license it outside cannabinoids; collaborate with Malaysia's Antah Group (LOI) on a clinical trial and commercialisation of medical cannabis in Malaysia; pursue new global distribution partners after H&H exclusivity expired.

FY2024–FY2026 (under administration): Preserve and grow the Australian medical cannabis business (THC flower pivot, new SKUs, more distributors); sell non-core IP; complete a restructuring with Biortica Agrimed providing "a sustainable source of debt and equity funding" (FY2025 report).

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

DateInitiativeStatus / outcome
Nov 2024Binding SPA to acquire Biortica via backdoor listing; Bod to be renamed "Biortica Agrimed Ltd"Abandoned Nov 2025
Nov 2024Sale of Aqua Phase, Schedule 3 data and CLIC Protein IP to Optimus Salvus (A$125,000 plus forgiveness of £2,000,000 debt claimed by Aqua Phase inventors)Completed 21 Nov 2024
FY2025THC portfolio expansion to 12 SKUs; distributors increased 2 → 5Completed; THC 73% of medical sales
FY2025Cost reduction: R&D -99%, marketing -96%, other expenses -67%, employee costs -59%Completed
Nov 2025DOCA variation: compulsory transfer of all shares to Biortica under s 444GACourt leave granted 19 Jun 2026
2,026DOCA completion; creditors' trust; retention of employeesScheduled 30 Jun 2026; effectuation not publicly confirmed

ESG/sustainability commitments and medium-term targets

No sustainability commitments, cost-program targets or medium-term financial targets have been published. No guidance has been issued since administration.

Products & Services

Medical segment

Product / brandDescriptionTarget customerLaunch / statusPricing
MediCabilis®GMP-certified, CBD-dominant full-spectrum cannabis oil; flagship product; supplied under SAS-B/Authorised Prescriber in Australia and as unlicensed special in UKPrescribing GPs/specialists; patients with chronic pain, anxiety, sleep and other unmet needsFirst imports Mar 2018; first prescription Oct 2018; UK via PCCA from Jul 2019. Units shipped: 12,187 (FY2021), 7,182 (FY2022), 3,419 (FY2023). Still sold FY2025 but declining.—
Bod Flora (THC range)THC flower and THC-containing medicinal cannabis productsAustralian prescribing clinics/patientsFirst THC product Dec 2023; 12 THC SKUs by FY2025; THC sales A$224,590 (FY2024), A$1,081,718 (FY2025, 73% of medical sales)Not publicly disclosed; FY2025 discounting to clear slow-moving stock
FGWMedicinal cannabis product range (named in FY2025 report alongside Bod Flora and MediCabilis); product specifics not disclosedAustralian patientsFY2025—
MediCabilis long-COVID applicationClinical study of MediCabilis for long-term COVID symptoms (announced FY2021)—Study status not disclosed after 2021—

OTC CBD/Hemp segment (exited/dormant)

Product / brandDescriptionMarketLaunch / status
CBIIConsumer CBD wellness range; four new products launched Apr 2020UK (later broadened UK footprint, Jun 2021)Inactive by FY2024
CBD products – NetherlandsConsumer CBD launchNetherlands/EUOct 2020; EU sales A$390,103 (FY2022) falling to A$4,258 (FY2023)
CBD products – United StatesGRAS status achieved Sep 2020; first binding PO Apr 2021USUS sales A$154,868 (FY2022), A$41,150 (FY2023), nil thereafter
H&H Group CBD/hemp supplyExclusive supply/licence of CBD and hemp products to Health & Happiness (HKSE: 1112)H&H brands (Swisse group)Sales A$1,281,098 (FY2022), A$294,565 (FY2023); exclusivity expired; capitalised H&H product-development costs impaired A$152,596 (FY2023)
Schedule 3 low-dose CBD soft gel (insomnia)Proprietary CBD soft-gel with patent-protected encapsulation intended for pharmacist-only sale; 50mg/100mg doses testedAustralian pharmacy consumersPhase IIb missed primary endpoint (2023); A$500,000 received from initial commercialisation (Arrotex exclusive distribution agreement); IP and data sold to Optimus Salvus Nov 2024

OTC Herbals segment (exited early 2H FY2024)

ProductDescriptionStatus
FlexofytolClinically studied turmeric extract for joint health, cartilage ageing and mild-arthritis inflammationExited FY2024
SedistressPassion-flower extract for stress, anxiety and insomnia symptomsExited FY2024
Other natural-medicine portfolio stocked by API/Symbion (2018)Not itemised in sources reviewedExited FY2024

Technology / IP assets (all sold)

AssetDescriptionStatus
Aqua PhaseProcess technology to increase bioavailability of lipophilic cannabinoids (oral CBD-in-oil bioavailability estimated at 6–8%); acquired for £1,000,000 (Aug 2023) with patent applicationImpaired A$1,946,283 (FY2024); sold Nov 2024
CLIC Protein IPNot described in detailSold Nov 2024
Soft gel/Schedule 3 clinical research and dataWoolcock Phase IIb data and dossierSold Nov 2024

Financial Narrative

Income statement

Sources: FY2021 results release (23 Aug 2021); FY2023 Appendix 4E (P&L, Note 7, Additional information); FY2025 Appendix 4E (P&L, Note 4, Additional information). EBITDA = EBIT + D&A (analyst calculation; not a company-reported metric). FY2021 sub-lines not available in primary sources reviewed. FY2020 net loss A$4.82m and FY2019 net loss A$7.62m (FY2020 release) for context.

Margins and growth

All margins on revenue from contracts with customers. FY2022 gross margin depressed by a one-off manufacturing cost; the company stated an underlying FY2022 gross margin of 33% vs 41% in FY2023. Revenue CAGR FY2021–FY2025: -31.2% (A$6.643m → A$1.485m).

Balance sheet

FY2021 equity and cash are the 1 July 2021 opening balances disclosed in the FY2023 statement of changes in equity and FY2022 cash flow statement. Of FY2025 trade payables of A$5.81m, A$1.17m were DOCA trading liabilities; the remainder largely represents pre-administration creditor claims compromised by the DOCA.

Cash flow

FY2024 intangibles capex of A$1.94m is predominantly the £1m Aqua Phase acquisition, impaired in the same year. FY2021 cash flows not available in sources reviewed; the Dec 2020 A$8m placement (gross) funded FY2021–FY2022 burn.

Ratios

ROE is not meaningful from FY2023 (negative equity); debt/equity not meaningful from FY2023; ROIC, net debt/EBITDA and interest coverage not meaningful in any year because EBIT and EBITDA were negative through FY2024 and FY2025 EBIT is driven by non-trading income; cash conversion cycle not computed because trade receivables and payables are distorted by DOCA-compromised claims. ROA and asset turnover use average total assets.

Commentary on trends, inflections and drivers

Revenue. The FY2020–FY2021 peak (A$6.1m and A$6.6m contract revenue) reflected two engines firing simultaneously: MediCabilis prescription growth (12,187 units in FY2021, up 212%) and CBD wellness sales of A$4.39m in FY2021, heavily weighted to H&H. Both engines then failed. Prescribing in Australia shifted decisively from CBD oils to THC flower, a trend management explicitly cited in FY2023 when MediCabilis units halved to 3,419; UK medical sales were also hit by supply-chain problems. Separately, the H&H exclusivity lapsed, removing roughly A$1.0m of high-volume (but lower-margin) sales between FY2022 and FY2023. The FY2025 rebound (+70%) is real but small, and reflects a late pivot into THC flower and expansion from two to five distributors.

Profitability. Bod never generated an operating profit from trading. The FY2023 loss widened to A$7.95m because R&D more than doubled to A$3.46m (Woolcock Phase IIb and Aqua Phase pharmacokinetic work) while revenue fell by half. FY2024's A$6.41m loss included A$3.33m of impairments (Aqua Phase A$1.95m, right-of-use asset A$1.30m, patents A$0.09m). The FY2025 profit of A$0.26m is an artefact of administration: Biortica funding income (A$1.17m), residual R&D incentives (A$0.68m) and the A$0.125m IP sale gain offset a medical segment that still lost A$0.43m.

Balance sheet. Equity swung from +A$8.7m (July 2021) to -A$5.3m (June 2024). The company was insolvent from about 30 June 2023 on the Deed Administrator's analysis accepted by the Court. The going-concern note in the FY2023 accounts already relied on further raises, borrowings (including Radium Capital R&D-advance loans) and Aqua Phase monetisation, none of which materialised.

Cash. Operating cash burn of A$4–6m a year against a sub-A$10m market capitalisation forced repeated dilutive raises at falling prices (A$0.08 in FY2023 vs highs of A$0.74 in FY2021). The failure of the November 2023 placement was the proximate trigger for administration.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment revenue (AUD Mn)

Segment revenue (AUD Mn)FY2022FY2023FY2024FY2025

Medical

1.7900.9330.6101.485

OTC CBD/Hemp (incl. royalty and other)

1.4570.5890.0100

OTC Herbals

0.4950.4400.2550

Corporate (R&D incentive, interest, other income)

1.5391.69000

Segment sales of goods + royalty (AUD Mn)

Segment sales of goods + royalty (AUD Mn)FY2022FY2023FY2024FY2025

Medical

1.6490.9330.6101.485

OTC CBD/Hemp

1.4570.3450.0100

OTC Herbals

0.4950.4400.2550

Total

3.6011.7180.8761.485

% contribution to revenue from contracts (%)

% contribution to revenue from contracts (%)FY2022FY2023FY2024FY2025

Medical (%)

45.854.369.7100.0

OTC CBD/Hemp (%)

40.520.11.20.0

OTC Herbals (%)

13.725.629.10.0

YoY growth in segment sales (%)

YoY growth in segment sales (%)FY2023FY2024FY2025

Medical (%)

-43.4-34.6143.4

OTC CBD/Hemp (%)

-76.3-97.0-100.0

OTC Herbals (%)

-11.0-42.0-100.0

Segment profit/(loss) before tax (AUD Mn)

Segment profit/(loss) before tax (AUD Mn)FY2022FY2023FY2024FY2025

Medical

-0.913-1.418-1.125-0.433

OTC CBD/Hemp

-1.161-0.2700.074-0.142

OTC Herbals

-0.368-0.427-0.1030

Corporate

-2.964-5.838-5.2590.834

Group

-5.407-7.953-6.4130.259

Segment pre-tax margin on segment sales (%)

Segment pre-tax margin on segment sales (%)FY2022FY2023FY2024FY2025

Medical (%)

-55.4-151.9-184.4-29.2

OTC Herbals (%)

-74.5-97.1-40.3—

Group Entities

EntityJurisdictionStatus

Bod Science Limited (parent)

Australia

Subject to DOCA; delisted 1 Dec 2025

Bod Healthcare Ltd

United Kingdom

Dissolved 12 Aug 2025

Aqua Phase Ltd (subsidiary of Bod Healthcare Ltd)

United Kingdom

Incorporated (acquired as dormant shelf) 3 Aug 2023; dissolved 10 Dec 2024

Other subsidiaries

Not individually disclosed in sources reviewed

The FCA judgment describes an "international group" whose subsidiaries' equity was valued at nil

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue from contracts with customers (AUD Mn)

6.6433.6011.7180.8761.485

Revenue incl. other revenue, legacy presentation (AUD Mn)

7.4205.0803.321——

Revenue YoY growth (%)

—-45.8-52.3-49.069.6

Cost of sales – raw materials and consumables (AUD Mn)

—2.9261.0220.6101.147

Gross profit (AUD Mn)

—0.6740.6960.2660.338

R&D expense (AUD Mn)

—1.6813.4621.2060.018

Employee/director benefits (AUD Mn)

—3.2853.0481.9680.816

Impairments – intangibles, ROU, inventory, receivables (AUD Mn)

—0.0220.2803.4390.179

Operating income / EBIT (AUD Mn)

—-5.412-7.941-6.2760.288

Depreciation and amortisation (AUD Mn)

—0.1540.1720.2090.024

EBITDA (AUD Mn)

—-5.258-7.769-6.0670.312

Interest expense (AUD Mn)

—00.0270.1520.050

Pre-tax income (AUD Mn)

-4.226-5.407-7.953-6.4130.259

Income tax (AUD Mn)

00000

Net income (AUD Mn)

-4.226-5.407-7.953-6.4130.259

EPS basic (AUD cents)

-4.26-5.10-5.63-3.680.15

EPS diluted (AUD cents)

-4.26-5.10-5.63-3.680.15

Dividends per share (AUD cents)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

—18.740.530.422.7

Operating (EBIT) margin (%)

—-150.3-462.2-716.819.4

EBITDA margin (%)

—-146.0-452.2-692.921.0

Net margin (%)

-63.6-150.1-462.9-732.417.4

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (AUD Mn)

—5.3133.5042.3072.597

Cash and equivalents, gross (AUD Mn)

8.0533.6662.0310.4341.098

Short-term borrowings / overdraft (AUD Mn)

—00.9630.4600.461

Lease liabilities, current (AUD Mn)

—001.3701.141

Long-term debt (AUD Mn)

—0000

Net debt incl. leases (AUD Mn)

—-3.666-1.0681.3960.505

Trade and other payables (AUD Mn)

—1.3411.6545.4465.814

Total liabilities (AUD Mn)

—1.8474.2077.6257.751

Total equity (AUD Mn)

8.6613.467-0.703-5.318-5.154

Goodwill (AUD Mn)

—0000

Intangibles (AUD Mn)

—0.4150.1310.0220.003

Inventories (AUD Mn)

—0.5560.2890.6710.408

Working capital (AUD Mn)

—3.099-0.320-5.298-5.099

Accumulated losses (AUD Mn)

23.88429.29137.24441.02940.626

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (AUD Mn)

—-4.176-5.678-0.9140.937

Capex – PP&E plus intangibles (AUD Mn)

—0.2070.1481.9590

Free cash flow (AUD Mn)

—-4.384-5.826-2.8730.937

Equity raised, net (AUD Mn)

—03.2021.7840

Borrowings raised, net (AUD Mn)

—00.9360.1830

Borrowings repaid (AUD Mn)

—001.1210

R&D incentive received (AUD Mn)

—1.1531.5132.0100.678

Biortica funding received in cash (AUD Mn)

—000.9670.923

Dividends paid (AUD Mn)

00000

Buybacks (AUD Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025

ROE (%)

-89.2———

ROA (%)

—-180.4-220.710.6

Current ratio (x)

2.740.910.300.34

Debt/equity (x)

0———

Asset turnover (x)

—0.390.300.61

Region – sales to external customers (AUD Mn)

Region – sales to external customers (AUD Mn)FY2022FY2023FY2024FY2025

Australia

1.9981.3140.7781.477

United Kingdom

0.8820.3090.0980.008

European Union

0.3900.00400

United States

0.1550.04100

Total

3.4251.6680.8761.485

Regional YoY growth

Regional YoY growthFY2023FY2024FY2025

Australia (%)

-34.3-40.889.9

United Kingdom (%)

-64.9-68.3-91.6

European Union (%)

-98.9-100.00.0

United States (%)

-73.4-100.00.0

Regional share of sales (%)

Regional share of sales (%)FY2022FY2023FY2024

Australia (%)

58.378.888.8

United Kingdom (%)

25.718.511.2

European Union (%)

11.40.30.0

United States (%)

4.52.50.0

Per-Share Data

MetricFY2019FY2020FY2021FY2022FY2023FY2024FY2025

Share price at 30 June (AUD cents)

34.027.033.57.06.92.42.4

Share price high (AUD cents)

66.072.074.036.017.012.52.4

Share price low (AUD cents)

22.012.025.57.04.62.42.4

Loss/profit per share (AUD cents)

-11.59-5.40-4.26-5.10-5.63-3.680.15

Share Price & Returns

DateRaisePrice

Sep 2018

A$6.4m strategic placement

—

Aug 2019

A$1.2m option exercise (board/management)

—

Dec 2020

A$8m private placement

—

Sep–Oct 2022

A$3.5m (A$1.5m placement + A$2.0m entitlement)

A$0.08

Aug 2023

A$1.9m placement (with 1-for-2 options at A$0.10)

A$0.08

FY2024 total

A$1.78m net equity raised

—

Nov 2023

Placement announced; failed

—

“—” = not publicly disclosed.

Analyst Conclusions

Management guidance and consensus

No guidance has been issued since entering administration, and there is no analyst consensus. The only forward-looking statement is Biortica's written representation (22 Sep 2025) that planned capital raises and forecast revenue growth would provide positive cash flow sufficient to fund the combined group (FY2025 going-concern note).

Bull-case arguments (for the operating business under Biortica ownership)

  1. THC momentum: Medical sales grew 143% in FY2025 with THC at 73% of the mix; integration with a large-scale grower could convert this into a supply-advantaged brand.

  2. Clean slate: The DOCA extinguishes ~A$4.6m of legacy payables into a creditors' trust, leaving a near debt-free operating company with positive FY2025 operating cash flow.

  3. Minimal fixed costs: A four-person team and near-zero R&D/marketing spend mean incremental sales should flow through at improved margins once inventory clearance ends.

Bear-case arguments

  1. Sub-scale and still loss-making at segment level: Medical lost A$0.43m in FY2025; FY2025 group profit depended on A$1.17m of funder support.

  2. Margin compression: Gross margin fell to 23% in a price-competitive THC flower market.

  3. Execution risk at the acquirer: Biortica repeatedly missed ASX/audit conditions, forcing at least three DOCA extensions and abandonment of the relisting.

Catalysts and monitorables (next 12 months)

  • Confirmation of DOCA effectuation and share transfer to Biortica (scheduled 30 Jun 2026).

  • Creditors' trust distributions (unsecured 1.10–2.59 cents in the dollar; priority employees 100 cents).

  • Issue of capital-loss declaration to former shareholders.

  • Any renaming, rebranding or integration announcements by Biortica.

  • Any Biortica capital raise or alternative listing plan.

  • Removal of residual security registrations (e.g., Burleigh Heads Cannabis).

Concluding analyst verdict

Bod Australia (Bod Science) is a case study in how a first-mover small-cap can be undone by a market shift it did not control and a capital structure it could not sustain. Between 2018 and 2021 the company built genuine prescriber recognition for MediCabilis, assembled credible distribution (Symbion, API, PCCA) and secured a high-profile partner in Health & Happiness. Revenue reached A$6.6m in FY2021. But the model rested on CBD at precisely the moment Australian prescribing pivoted to THC flower, and on a single large customer whose exclusivity lapsed. Instead of retrenching, management doubled R&D in FY2023 to pursue a Schedule 3 insomnia product whose pivotal trial then missed its primary endpoint, and committed £1m to the Aqua Phase technology weeks before a funding round failed. The resulting insolvency, dated by the Deed Administrator to about June 2023, wiped out more than A$40m of accumulated shareholder capital.

For former equity holders the outcome is final: the Federal Court accepted an independent valuation of nil and granted leave to transfer every share and option to Biortica Agrimed without consideration. There is no residual investment case in the listed security, which no longer exists.

For creditors, suppliers, competitors and potential partners, the relevant question is whether the operating business, now a four-person THC-flower distributor with A$1.5m of revenue, has a future inside Biortica. The FY2025 numbers show real top-line momentum and positive operating cash flow, but segment-level trading remains loss-making, margins are thin and the business is wholly dependent on its new owner's funding and execution, which has been inconsistent. The most likely trajectory is absorption into Biortica as a downstream brand and distribution channel rather than revival as a standalone company. Stakeholders should monitor DOCA effectuation, creditor distributions and any Biortica capital-raising disclosures.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenureBackground / educationFY2023 total remuneration (AUD)FY2025 total remuneration (AUD)

Joanne (Jo) Patterson

Founder, CEO and Executive Director; Company Secretary since 6 May 2025

Founded 2014; CEO agreement from 5 Sep 2016

MBus (Marketing), University of Technology Sydney; 20+ years across technology, advertising and beauty businesses

524,465154,321

David Baker

Non-Executive Chairman; Chair, Audit & Risk

Joined FY2022

BA, LLB (Hons); 40+ years law, investment banking; co-founder Baker Cook Advisory; former director Mineral Commodities Ltd

89,3680

George Livery

Non-Executive Director; Chair, Remuneration & Nominations

Since ~2018

FAMI; ex-CEO Village Cinemas Australia; Commercial Director Swisse; led Swisse integration into H&H; former Chair, Hydration Pharmaceutical Co. (retired May 2024)

66,1860

Akash Bedi

Non-Executive Director (H&H nominee in substance)

Since ~Dec 2020

BEng (Manipal), MBA (Cardiff); Chief Strategy & Operations Officer, Health & Happiness International; ex-HSBC M&A; director, Else Nutrition

66,1860

Craig Weller

Chief Technology Officer

Since 5 Sep 2016

—432,810146,291

Adrian Sturrock

Chief Financial Officer

2 Aug 2021 – resigned 2025 (after ~4 years; exact date not confirmed)

—414,341325,832

Hanno Cappon

Non-Executive Director

Resigned 9 Nov 2022

—19,095—

Carlie Hodges

Company Secretary

23 Jan 2023 – 6 May 2025

Corporate lawyer; FGIA

——

Former NEDs (FY2022): Mark Masterson, Simon O'Loughlin, Patrice Malard

Non-Executive Directors

Departed during FY2022

—

FY2022: 62,315 / 39,377 / 11,049

—

“—” = not publicly disclosed.

Directors' Remuneration

Component (AUD)Patterson FY2023Patterson FY2025Weller FY2023Weller FY2025Sturrock FY2023Sturrock FY2025

Cash salary

372,766125,000308,636125,000288,952292,485

Cash bonus

72,526061,014057,4810

Superannuation

22,94814,37524,26714,37524,67230,000

Share-based payments

47,4489,44348,4666,87336,7116,475

Total

524,465154,321432,810146,291414,341325,832

Major Shareholders

HolderShares%Source / date

HSBC Custody Nominees (Australia) Ltd

29,061,13016.39

Market Index top holders (latest register)

SG Hiscock & Company Ltd

10,416,351

8.53 (at time of notice; ~5.9% of current 177.3m shares)

Substantial holder notice 20 Sep 2023

Jo Patterson (CEO)

7,175,0004.05

FY2025 report

David Baker (Chair)

6,375,0003.59

FY2025 report

Health And Beauty Enterprise Pty Ltd

6,375,0003.59

Market Index / Motley Fool top holders (ceased substantial holding 22 Aug 2023)

Craig Weller (CTO)

4,852,3292.74

FY2025 report

Citicorp Nominees Pty Ltd

4,506,5362.57

Motley Fool top holders

George Livery

395,2950.22

FY2025 report

Adrian Sturrock

300,0000.17

FY2025 report

Competitive Landscape

Competitors by Segment

SegmentCompetitorTypeRelative positioning vs Bod

Medical cannabis (AU)

Montu / Alternaleaf

Private telehealth-plus-supply platform

Far larger; vertically integrated patient acquisition, dominant in THC flower prescribing

Medical cannabis (AU)

Little Green Pharma (ASX: LGP)

Listed grower/manufacturer

Own cultivation and GMP manufacture; far larger scale

Medical cannabis (AU)

Cann Group (ASX: CAN)

Listed grower/manufacturer

Large-scale cultivation assets

Medical cannabis (AU)

Vitura Health (ASX: VIT)

Listed clinic/distribution platform

Larger distribution and clinic network

Medical cannabis (AU)

Australian Natural Therapeutics Group

Private cultivator/brand owner

Larger THC flower supplier

Medical cannabis (AU)

Cannatrek

Private cultivator/brand

Larger THC flower supplier

Medical cannabis (AU)

Biortica Agrimed / Apollo Green

Private B2B grower and genetics (self-described as Australia's largest vertically integrated commercial grower of medicinal plants)

Acquirer; supply-side partner

Medical cannabis (AU)

Zelira Therapeutics, Emyria (ASX: EMD)

Listed drug-development/clinic models

Comparable small-cap, R&D-led positioning

Medical cannabis (UK)

Health House International and UK specials suppliers

Distributors

Larger UK footprint

Consumer CBD (UK/EU/US)

Numerous private CBD brands

Fragmented consumer market

Bod exited

S3 CBD (AU)

Other sponsors pursuing S3 low-dose CBD registration

Pharma sponsors

No S3 CBD product reached Bod's market; Bod exited

OTC herbals (AU)

Blackmores, Swisse (H&H) and other VMS brands

Large VMS companies

Bod's herbal range was sub-scale and exited

Recent Developments

Because the company was suspended and in administration throughout this window, material disclosures were sparse. The register extends back to late 2024 to provide context.

Company Snapshot

7

Employees

2014

Founded

Sydney, Australia

Headquarters

SWOT Analysis

Strengths

  • THC pivot is gaining traction: THC sales rose from A$224,590 (FY2024) to A$1,081,718 (FY2025), 73% of medical sales (FY2025 4E).
  • Revenue rebound: FY2025 contract revenue +70% to A$1.48m; medical sales +143% (FY2025 4E).
  • Lean cost base: Employee/director costs cut 59% to A$0.82m; R&D cut 99%; marketing cut 96% (FY2025 4E).
  • Positive operating cash flow: A$0.94m in FY2025 vs -A$5.68m in FY2023 (cash flow statements), albeit funding-assisted.
  • Distribution breadth improving: Distributors increased from two to five in FY2025 (FY2025 4E).
  • Committed owner/funder: Biortica has funded trading costs (A$2.14m across FY2024–FY2025) over and above DOCA contributions ([2026] FCA 795; FY2025 4E).

Weaknesses

  • Deep insolvency: Net liabilities of A$5.15m at 30 June 2025; court-accepted liquidation deficiency of A$5.32m ([2026] FCA 795).
  • No trading profitability: Medical segment pre-tax loss of A$0.43m in FY2025 even after the THC rebound (FY2025 Note 4).
  • Margin erosion: Gross margin fell from 30% (FY2024) to 23% (FY2025) due to discounting and loss of higher-margin OTC lines (FY2025 4E).
  • Customer concentration: Three customers = 67% of FY2025 sales (FY2025 Note 4).
  • Asset-light with no proprietary IP left: Intangibles A$3,132; key IP sold Nov 2024.
  • Value-destroying capital allocation: Aqua Phase acquired for £1m in Aug 2023 and impaired A$1.95m within the same fiscal year (FY2024).

Opportunities

  • Vertical integration with Biortica: Access to a large-scale grower and genetics (Apollo Green) could improve supply cost and margin (Biortica/NZX release, Feb 2024).
  • THC SKU expansion: 12 THC SKUs launched since Dec 2023 provides a platform for further range extension (FY2025 4E).
  • Inventory normalisation: FY2025 inventory clearance (impairment A$179,100) leaves cleaner stock for margin recovery.
  • Creditor-claim cleansing: DOCA extinguishes pre-administration claims into a creditors' trust, leaving a debt-light operating company ([2026] FCA 795).
  • Tax losses: Unused tax losses of A$21.8m at FY2023 (potential benefit A$5.4m), though continuity-of-ownership tests likely fail after the share transfer (FY2023 Note 8).
  • Residual brand equity in MediCabilis among CBD prescribers.

Threats

  • DOCA completion risk: If the DOCA fails, liquidation is "practically inevitable" with nil return to creditors ([2026] FCA 795).
  • Funder dependence: Going concern relies on Biortica's ability to fund the business (FY2025 going-concern note).
  • Biortica execution record: Repeated delays meeting ASX conditions and audit requirements forced DOCA extensions in 2025 (Mar, Jun, Aug 2025 notices).
  • THC flower price competition led to discounting in FY2025 (FY2025 4E).
  • Potential voidable-transaction claim of ~A$1.674m identified for a liquidator ([2026] FCA 795).
  • Regulatory tightening in Australian medicinal cannabis (highly regulated sales, FY2025 risk section).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
31 Oct 2024Reliance on ASIC relief for externally administered bodies; 2024 AGM deferredReduced reporting obligations
Oct 2024Q1 FY2025 cash flow report: net outflow ~A$4k; receipts up 176% QoQBiortica funding stabilising operations
4–5 Nov 2024Binding SPA to acquire Biortica (backdoor listing)Proposed relisting path
21 Nov 2024IP sale to Optimus Salvus (A$125k plus £2m debt release)Removed large contingent creditor claim
10 Dec 2024Aqua Phase Ltd (UK) dissolvedSimplification
24 Jan 2025ASX release on executed asset sale deed for IP rightsFormal disclosure of IP sale
19 Mar 2025Notice to shareholders: DOCA extended to 30 Jun 2025 due to Biortica compliance and audit delaysTimetable slippage
9 Apr 2025Update on restructuring with BiorticaProcess continuation
6 May 2025Change of company secretary (Hodges out; Patterson in)Cost reduction
7 May 2025Registered office moved to Rodgers ReidyOffice exit
17 Jun 2025DOCA extended to 7 Aug 2025 after Biortica paymentSlippage
25 Jul 2025Appendix 4D for 1H FY2025: revenue A$600,659 (+38%); loss A$16,434 (-99.7%); gross margin 34%Late filing; THC pivot evidence
5 Aug 2025DOCA extended to 20 Nov 2025 after further Biortica paymentSlippage
12 Aug 2025Bod Healthcare Ltd (UK) dissolvedUK exit complete
2025 (approx. Aug–Sep)CFO Adrian Sturrock resigns after ~4 yearsManagement attrition
18 Sep 2025Notification of cessation of securitiesOption lapses
25 Sep 2025Notification of cessation of securities; change of director's interest noticeOption lapses
26 Sep 2025FY2025 Appendix 4E and annual report: revenue A$1.48m (+70%); profit A$0.26mFirst reported annual profit (non-trading driven)
Oct–Nov 2025EGM expected by late Nov 2025, delayed by audit completion issuesNot held as originally planned
25 Nov 2025Letter to shareholders: Biortica RTO no longer proceeding; DOCA variation with s 444GA share transfer; creditor vote mid-to-late Dec 2025; capital loss declaration intendedShareholders to be expropriated at nil value
1 Dec 2025Removed from ASX Official List (after two-year suspension)End of listed status
Dec 2025Creditors' vote on DOCA variation (outcome implied favourable by subsequent court process)Enabled court application
14 May 2026Federal Court procedural orders; notice to creditors and membersNo opposition filed
3 Jun 2026Deed Administrator applies to ASIC for Chapter 6 reliefASIC in-principle relief granted conditional on court orders
19 Jun 2026Jackman J grants s 444GA leave (NSD 746 of 2026)Shares and options to transfer to Biortica
30 Jun 2026Scheduled DOCA completion dateEffectuation not publicly confirmed

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit: Revenue from contracts with customers fell from AUD 6.6 Mn in FY2021 to AUD 1.5 Mn in FY2025.
Bod Australia Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2021FY2022FY2023FY2024FY2025
Revenue from contracts with customers6.63.61.70.91.5
Revenue incl. other revenue, legacy presentation7.45.13.3——
Cost of sales – raw materials and consumables—2.910.61.1
Gross profit—0.70.70.30.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.